No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NMRA Neumora Therapeutics
- 9.780
- -0.170-1.71%
Close Jun 14 16:00 ET
- 9.990
- +0.210+2.15%
Post 19:19 ET
1.56BMarket Cap-6135P/E (TTM)
10.180High9.550Low376.38KVolume9.840Open9.950Pre Close3.69MTurnover0.46%Turnover RatioLossP/E (Static)159.52MShares21.00052wk High3.68P/B809.03MFloat Cap8.82052wk Low--Dividend TTM82.72MShs Float21.000Historical High--Div YieldTTM6.33%Amplitude8.820Historical Low9.814Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
BofA Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $22
BofA Securities analyst Geoff Meacham maintains $Neumora Therapeutics(NMRA.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 4
This Neumora Therapeutics Insider Increased Their Holding In The Last Year
Express News | Neumora Therapeutics Inc : JP Morgan Cuts Target Price to $18 From $22
Express News | Neumora Therapeutics Initiates Phase 2 Study Of Navacaprant In Bipolar Depression, Expects To Report Topline Data In Second Half Of 2025
Express News | Neumora: Expects to Report Topline Data From Phase 2 Navacaprant Study in Second Half of 2025
Express News | Neumora Therapeutics Inc: Data From Koastal-1 Anticipated in Q4
Comments
Ms. Pai Panandiker's appointment, with her vast neuropsychiatry commercial expertise, is seen as invaluable for Neumora's potential commercialization of navacaprant and pipeline advancement. Her experience in neuroscience product commercialization is expected to boost Neumora's growth.
Press Release: Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer 1
CEO of Neumora Therapeutics is optimistic over Mr. Duncan's appointment due to his legal expertise and program strategy, valuable to the company's goal of advancing neuroscience drug development. Duncan highlights Neumora's leading brain disorder pipeline and recent clinical progress.
CEO of Neumora, Henry Gosebruch, values Dr. Lenz's successful trial experience and neuroscience expertise for their pipeline development. Dr. Lenz is excited to contribute significantly to Neumora's R&D and neuropsychiatry programs.
$Axcella Health(AXLA.US$ Ranked #1 by Fintel. Its next run should take it to about 14.90.
$Ontrak(OTRK.US$ Has been out of shares for a week. Small float and cheap price. Can run as high as 2.94 when it finally does get volume.
$Neumora Therapeutics(NMRA.US$ Recent IPO and has been steady moving up from its low of 9.80. Now comes the bigger gap ups . 17.74 is its breakout.
$Prestige Wealth(PWM.US$ Seems to have found bottom at 3.10. If it has ER on October 6 that is. S...
$Ontrak(OTRK.US$ Has been out of shares for a week. Small float and cheap price. Can run as high as 2.94 when it finally does get volume.
$Neumora Therapeutics(NMRA.US$ Recent IPO and has been steady moving up from its low of 9.80. Now comes the bigger gap ups . 17.74 is its breakout.
$Prestige Wealth(PWM.US$ Seems to have found bottom at 3.10. If it has ER on October 6 that is. S...
7
9
McHTP
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg